产品名称 |
SUP-B15人Ph+急淋白血病细胞系 |
货号 |
ZQ0417 |
产品介绍 |
SUP-B15 是一种 B 淋巴母细胞系,是从一名患有急性淋巴细胞白血病 (ALL) 的 8 岁白人男性患者的骨髓中分离出来的。这些细胞表达多种 B 谱系标记,但不表达 T 细胞标记。这些细胞的 β-2-微球蛋白、Leu12、My7 (CD13)、OKT9 (CD71)、OKT10 (CD38) 和 CALLA (CD10) 抗原呈阳性。
CB1、Leu 1 (CD5)、Leu2 (CD8)、Leu3 (CD4)、Leu4 (CD3)、Leu5 (CD2)、Leu6 (CD1a)、Leu9、Leu M1 (CD15)、My9 (CD33) 均为阴性、表面免疫球蛋白(sIg-)和 Epstein-Barr 病毒。 |
种属 |
人 |
性别/年龄 |
男/8岁 |
组织 |
骨;骨髓 |
疾病 |
急性淋巴细胞白血病 |
细胞类型 |
肿瘤细胞 |
形态学 |
成淋巴细胞 |
生长方式 |
悬浮 |
倍增时间 |
~18 hours (PubMed=3162827); ~60 hours (DSMZ=ACC-389) |
培养基和添加剂 |
RPMI-1640(中乔新舟 货号:ZQ-200)+10%胎牛血清(中乔新舟 货号:ZQ0500)+1%双抗(中乔新舟 货号:CSP006)+β-Mer 终浓度:0.05mM(中乔新舟 货号:CSP005,例:500ml添加500ul) |
推荐完全培养基货号 |
|
生物安全等级 |
BSL-1 |
STR位点信息 |
Amelogenin: X,Y CSF1PO: 11,12 D13S317: 8,14 D16S539: 11,12 D5S818: 12,13 D7S820: 10,11 THO1: 6,9.3 TPOX: 8,9 vWA: 15,17 |
培养条件 |
95%空气,5%二氧化碳;37℃ |
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
ATCC; CRL-1929 DSMZ; ACC-389 |
供应限制 |
仅供科研使用 |
货号 |
ZQ0417 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
PubMed=3162827
Naumovski L., Morgan R., Hecht F., Link M.P., Glader B.E., Smith S.D.
Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines without classical breakpoint cluster region rearrangement.
Cancer Res. 48:2876-2879(1988)
PubMed=7630190
Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)
PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608
Zhou M.-X., Yeager A.M., Smith S.D., Findley H.W.
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Blood 85:1608-1614(1995)
PubMed=8704231; DOI=10.1182/blood.V88.3.785.785
Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y., Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D., Smith S.D.
TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines.
Blood 88:785-794(1996)
PubMed=9067587; DOI=10.1038/sj.leu.2400571
Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A., Janssen J.W.G., Drexler H.G.
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Leukemia 11:441-447(1997)
PubMed=9108419; DOI=10.1182/blood.V89.8.2986
Findley H.W., Gu L.-B., Yeager A.M., Zhou M.-X.
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Blood 89:2986-2993(1997)
PubMed=9823951; DOI=10.1038/sj.leu.2401198
Zhou M.-X., Gu L.-B., Yeager A.M., Findley H.W.
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Leukemia 12:1756-1763(1998)
PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4
Drexler H.G., MacLeod R.A.F., Uphoff C.C.
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Leuk. Res. 23:207-215(1999)
PubMed=10576511; DOI=10.1016/s0145-2126(99)00131-9
Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.
ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.
Leuk. Res. 23:1055-1060(1999)
DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)
PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)
PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)
PubMed=25576301; DOI=10.1074/mcp.M114.042812
Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Mol. Cell. Proteomics 14:658-673(2015)
PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)
PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)
PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)
PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014
Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C., Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J., Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N., Muller I., Walles H., Hartmann W., Rossig C.
EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells.
Mol. Ther. 27:933-946(2019)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=35354797; DOI=10.1038/s41467-022-29224-5
Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T., Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E., Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I., Lehtio J., Vesterlund M., Jafari R.
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.
Nat. Commun. 13:1691.1-1691.19(2022)
PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)